Trial Profile

A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENT 01 (Primary)
Indications Dementia; Parkinson's disease
Focus Therapeutic Use
Sponsors Enterin

Most Recent Events

28 Feb 2024 Planned initiation date changed from 15 Jan 2024 to 1 Mar 2024.
28 Feb 2024 Status changed from suspended to discontinued.
08 Jun 2023 Planned End Date changed from 25 May 2021 to 15 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com